REGENXBIO Inc. (RGNX)
Automate Your Wheel Strategy on RGNX
With Tiblio's Option Bot, you can configure your own wheel strategy including RGNX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
REGENXBIO, Inc. Class Action Reminder - Robbins LLP Encourages RGNX Stockholders to Contact the Firm for Information About Their Rights
Published: April 03, 2026 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO, April 3, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired REGENXBIO, Inc. (NASDAQ: RGNX) securities between February 9, 2022 and January 27, 2026. REGENXBIO is a clinical-stage biotechnology company providing gene therapies that deliver functional genes to cells with genetic defects in the United States.
Read More
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm
Published: April 03, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of PayPal Holdings, Inc. (NASDAQ:PYPL) and REGENXBIO Inc. (NASDAQ:RGNX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Read More
RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit — The Gross Law Firm
Published: March 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of REGENXBIO Inc. (NASDAQ: RGNX).
Read More
RGNX INVESTOR ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
Published: March 27, 2026 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in REGENXBIO between February 9, 2022 and January 27, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - March 27, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against REGENXBIO Inc. ("REGENXBIO" or …
Read More
RGNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
Published: March 24, 2026 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options
Read More
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Published: March 23, 2026 by: GlobeNewsWire
Sentiment: Neutral
New class action for REGENXBIO Inc. (RGNX) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/14/2026.
Read More
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: March 23, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, March 23, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against REGENXBIO Inc. (“Regenxbio” or “the Company”) (NASDAQ: RGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before April 14, 2026.
Read More
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
Published: March 20, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 20, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”), of the important April 14, 2026 lead plaintiff deadline.
Read More
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm
Published: March 19, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of PayPal Holdings, Inc. (NASDAQ:PYPL) and REGENXBIO Inc. (NASDAQ:RGNX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Read More
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Published: March 19, 2026 by: GlobeNewsWire
Sentiment: Neutral
New class action for REGENXBIO Inc. (RGNX) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/14/2026.
Read More
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: March 19, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, March 19, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against REGENXBIO Inc. (“Regenxbio” or “the Company”) (NASDAQ: RGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before April 14, 2026.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX
Published: March 19, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, March 19, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against REGENXBIO Inc. ("Regenxbio" or the "Company") (NASDAQ: RGNX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
RGNX DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
Published: March 19, 2026 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options
Read More
FDA reversals leave investors worrying about the fates of other experimental drugs
Published: March 06, 2026 by: CNBC
Sentiment: Negative
The FDA in the past year has denied or discouraged applications of at least eight new drugs, according to RTW Investments. The agency initially refused to review Moderna's flu shot before reversing course.
Read More
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: March 06, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, March 06, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against REGENXBIO Inc. (“Regenxbio” or “the Company”) (NASDAQ: RGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before April 14, 2026.
Read More
RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST
Published: March 05, 2026 by: PRNewsWire
Sentiment: Neutral
Promise vs. Reality: The REGENXBIO Gene Therapy Performance Gap NEW YORK, March 5, 2026 /PRNewswire/ -- "Very promising results.
Read More
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
Published: March 05, 2026 by: Zacks Investment Research
Sentiment: Negative
Regenxbio (RGNX) came out with a quarterly loss of $1.3 per share versus the Zacks Consensus Estimate of a loss of $1.01. This compares to a loss of $1.01 per share a year ago.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
Published: March 03, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against REGENXBIO Inc. (“Regenxbio” or the “Company”) (NASDAQ: RGNX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: March 03, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, March 03, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against REGENXBIO Inc. (“Regenxbio” or “the Company”) (NASDAQ: RGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before April 14, 2026.
Read More
RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
Published: February 27, 2026 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in REGENXBIO between February 9, 2022 and January 27, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 27, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against REGENXBIO Inc. ("REGENXBIO" or the "Company") (NASDAQ: …
Read More
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: February 27, 2026 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 27, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against REGENXBIO Inc. ("Regenxbio" or "the Company") (NASDAQ: RGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before April 14, 2026.
Read More
REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX
Published: February 27, 2026 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 27, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against REGENXBIO Inc. ("Regenxbio " or "the Company") (NASDAQ: RGNX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of RGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX
Published: February 26, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against REGENXBIO Inc. ("Regenxbio" or the "Company") (NASDAQ: RGNX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Published: February 26, 2026 by: GlobeNewsWire
Sentiment: Neutral
New class action for REGENXBIO (RGNX) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of Apr. 14, 2026.
Read More
Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors
Published: February 26, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises REGENXBIO, Inc., (“REGENXBIO” or the "Company") (NASDAQ: RGNX) investors of a class action on behalf of investors that bought securities between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”). REGENXBIO investors have until April 14, 2026 to file a lead plaintiff motion.
Read More
Regenxbio (RGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Published: February 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: February 24, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 24, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against REGENXBIO Inc. (“Regenxbio” or “the Company”) (NASDAQ: RGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before April 14, 2026.
Read More
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: February 23, 2026 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 23, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against REGENXBIO Inc. ("Regenxbio" or "the Company") (NASDAQ: RGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before April 14, 2026.
Read More
REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX
Published: February 23, 2026 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 23, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against REGENXBIO Inc. ("Regenxbio " or "the Company") (NASDAQ: RGNX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of RGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
Read More
ROSEN, LEADING TRIAL ATTORNEYS, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
Published: February 22, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - February 22, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed.
Read More
About REGENXBIO Inc. (RGNX)
- IPO Date 2015-09-17
- Website https://www.regenxbio.com
- Industry Biotechnology
- CEO Curran Simpson
- Employees 353